| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00296062 Details | 2012-01-16 Interventional | 1 | 12 | Bevacizumab Capecitabine Irinotecan Oxaliplatin Colorectal Neop… Colorectal Canc… Unspecified Adu… | Trial did not move to Phase II portion due to poor tolerance of treatment - | |||
| NCT00245128 Details | 2012-01-13 Interventional | 2 | 10 | Imatinib Mesyla… Myeloproliferat… Primary Myelofi… Chronic Myelopr… | Per PI, results from another similar study were published prior to study analysis. Negative
study results were published therefore analysis was not completed Early termination/results were never analyzed due to negative study results from other similar studies. | |||
| NCT01416870 Details | 2012-01-11 Interventional | 1 | 102 | Bicalutamide Healthy | - - | |||
| NCT01252342 Details | 2012-01-11 Interventional | 4 | 0 | Oxytocin Hemorrhage Postpartum Hemo… Uterine Inertia Uterine Atony | Proposed doses were too large, bolus oxytocin may cause cases of arrythmias, and some even
advocate slowing down the infusion rates that are currently used. - | |||
| NCT00492388 Details | 2012-01-11 Interventional | 3 | 2 | Ketamine Breakthrough Pa… Cancer Pain | Business decision not to continue development - | |||
| NCT00969293 Details | 2012-01-10 Interventional | 1 | 11 | Ecallantide Edema Macular Edema Retinal Vein Oc… Central Retinal… | - - | |||
| NCT01233947 Details | 2012-01-09 Interventional | 2 | 7 | Fulvestrant Breast Neoplasm… Breast Neoplasm | - - | |||
| NCT00159575 2004-001124-20 Details | 2012-01-05 Interventional | 4 | [1 Refs] | 150 | Metformin Polycystic Ovar… Syndrome | Slow patient recruitment and expiry of study medication(aug2009) - | ||
| NCT01169870 Details | 2012-01-04 Interventional | 2 | 0 | Paclitaxel genexol-PM Breast Neoplasm… Breast Cancer | withdrawn studies - | |||
| NCT01412515 Details | 2012-01-02 Interventional | 2 | 11 | Everolimus Sarcoma Sarcoma, Kaposi Kaposi Sarcoma | results from interim analysis conducted to study interruption - | |||
| NCT00504491 2007-003097-26 Details | 2011-12-30 Interventional | 2 | 0 | Alemtuzumab Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… Patients Relaps… Patients Resist… | IMP new owner decision - | |||
| NCT01080768 2009-014359-63 Details | 2011-12-26 Interventional | 2 | 31 | Aliskiren Amlodipine Hypertension Ankle Edema | Publication of data from a similar study made the current study redundant. - | |||
| NCT00401401 Details | 2011-12-23 Interventional | 1/2 | 30 | Zalutumumab Carcinoma, Squa… Head and Neck N… Neoplasms, Squa… Head and Neck C… Squamous Cell C… | MTD was established and patients completed 16 months safety f-up and response assessments. It
is considered of limited value to follow patients for 3 years. All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years. The planned parallell group of the study was cancelled. | |||
| NCT01106235 Details | 2011-12-21 Interventional | 1 | - | Aldesleukin Cyclophosphamid… Interleukin-2 Melanoma Stage IV Melano… | - - | |||
| NCT00946907 Details | 2011-12-21 Interventional | 4 | 34 | Aspirin Pericarditis | This study was suspended by principal investigator's decision. All the sites were not opened,
and the recruitment was so slow. - | |||
| NCT01441388 Details | 2011-12-20 Interventional | 1 | 0 | Axitinib Bevacizumab Crizotinib Sorafenib Sunitinib Carcinoma Carcinoma, Hepa… Carcinoma, Rena… Glioblastoma | Business/Operational issues - | |||
| NCT00238355 Details | 2011-12-19 Interventional | 2 | 13 | Caspofungin Voriconazole Communicable Di… Infections Invasive Fungal… Mycoses Infection Unspecified Adu… | competing study at site - | |||
| NCT00217152 Details | 2011-12-19 Interventional | 4 | 12 | Mycophenolic Ac… Delayed Graft F… Kidney Transpla… | Roche decided to prematurely terminate study. - | |||
| NCT01210443 Details | 2011-12-14 Interventional | 3 | 2 | Sitaxsentan Hypertension Hypertension, P… Pulmonary Arter… | Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,
specifically new emerging evidence of hepatic injury. - | |||
| NCT00802048 Details | 2011-12-13 Interventional | 3 | 21 | Anesthetics Anesthetics, Lo… Ropivacaine Hyperalgesia Pain | - - |